Archive for November 2021
PK/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients.
Willmann S., Marostica E., Snelder N., Solms A., Jensen M., Lobmeyer M., Lensing A. W. A., Bethune C., Morgan E., Yu R. Z., Wang Y., Jung S. W., Geary R., Bhanot S. PK/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients. CPT Pharmacometrics Syst.…
Read MoreFinerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III
van den Berg P, Ruppert M, Mesic E, Snelder N, Seelmann A, Heinig R, Joseph A, Garmann D, Lippert J, Eissing T. Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis. Clin Pharmacokinet. 2021. . [Link to publication]
Read MoreFinerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III
Goulooze SC, Snelder N, Seelmann A, Horvat-Broecker A, Brinker M, Joseph A, Garmann D, Lippert J, Eissing T. Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria. Clin Pharmacokinet. 2021. [Link to publication]
Read More